KLRS Kalaris Therapeutics, Inc.: institutional ownership and insider trading
56 funds reported holding $75.8M of Kalaris Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $2.23M, with 9 new positions and 11 funds selling out; over the last 12 months insiders bought $6.18M and sold $12.9K on the open market.
Famous investors holding KLRS
- Renaissance Technologies (Renaissance Technologies): $608K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $390K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $97.1K, 0.0% of the portfolio
Largest institutional holders of KLRS
- Samsara BioCapital, LLC — $52.4M
- RTW INVESTMENTS, LP — $5.29M
- VANGUARD GROUP INC — $2.47M
- Alyeska Investment Group, L.P. — $2.33M
- Siren, L.L.C. — $1.77M
- VANGUARD CAPITAL MANAGEMENT LLC — $1.62M
- Ikarian Capital, LLC — $1.47M
- UBS Group AG (UBS) — $1.07M
- RENAISSANCE TECHNOLOGIES LLC — $608K
- MARSHALL WACE, LLP — $567K
Recent KLRS insider trades
- May 20, 2026: Akkaraju Srinivas bought 244,300 shares ($1.18M)
- Mar 20, 2026: Hagen Brett R sold 1,915 shares ($12.9K)
- Dec 18, 2025: Akkaraju Srinivas bought 479,847 shares ($5.00M)
- Mar 26, 2025: Hagen Brett R sold 907 shares ($8.14K)
5%+ owners
- Srinivas Akkaraju: 54.2% (Schedule 13D/A, filed May 22, 2026)